ATAI LIFE SCIENCES N.V. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.745 USD | -6.18% |
|
-7.67% | +23.76% |
| May. 15 | Atai Life Sciences N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 15 | Atai Life Sciences N.V. Announces CEO Changes | CI |
Presenter SpeechJudah Frommer (Analysts)Hi, everyone, and welcome to day 4 of the 2021 Credit ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.86
USD
Average target price
11.8
USD
Spread / Average Target
+534.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.76% | 311M | |
| +32.76% | 50.85B | |
| +0.11% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +10.95% | 26.11B | |
| -22.13% | 19.13B | |
| +8.11% | 13.05B | |
| +27.57% | 12.16B | |
| +24.59% | 12.08B |
- Stock Market
- Equities
- ATAI Stock
- News Atai Life Sciences N.V.
- Transcript : Atai Life Sciences N.V. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-11-2021 09